Article Text

This article has a correction. Please see:

Download PDFPDF
Experimental therapeutics—preclinical
P05 ED11—a novel huntington based peptide as a CASPASE-6 inhibitor
  1. I Aharony,
  2. D Offen
  1. Neuroscience Laboratory, Felsenstein Medical Research Center-Tel Aviv University, Petah Tikva, Israel


Background Caspase-6 involvement in Huntington's disease (HD) is now well established, as caspase-6 has a key role in the apoptotic events seen in HD. It has been shown that caspase-6 is activated early in the disease course, inducing different cellular dysfunctions. Importantly, caspase-6 proteolysis of mutant huntingtin is known to be an essential process in generating toxic N-terminal fragments, which leads to neurodegeneration and symptoms onset. Therefore, interfering with caspase-6 activity was suggested as a promising therapeutic target for reducing mutant huntingtin toxicity, and rescuing neuronal cells from degeneration.

Aims The aim of this study is to develop a novel peptide (ED11), based on huntingtin Caspase-6 cleavage site, and fused to a cell penetrating peptide, which will serve as an efficient competitive inhibitor of caspase-6 cleavage, thus reducing HD related toxicity.

Methods Using purified caspase-6 activity luminescence assay, the peptide (ED11) caspase-inhibition ability was measured. To test ED11 ability to protect cells from HD related toxicity, neuronal (SH-SY5Y) cells were placed under glutamate toxicity and three parameters were tested: Caspase-6 activity was measured using FLICA in-cell caspase activity assay, cell viability was measured by Alamar blue assay, and cell apoptosis was assessed using annexin V-PI flow-cytometry analysis.

Results We have demonstrated that ED11 significantly reduces caspase-6 specific activity. Moreover, in neuronal cells it inhibited caspase-6 activity under stress, and protected the cells from glutamate toxicity, an important factor in the pathogenesis of HD. Importantly, ED11 was found to be non-toxic to neuronal cells even in high doses.

Conclusions ED11 was shown to inhibit caspase-6 activity and provided protection against glutamate toxicity in vitro. These results show the potential of ED11 as a novel therapeutic compound in HD.

  • Huntington's disease
  • caspase-6
  • peptide therapy
  • ED11

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Corrections
    BMJ Publishing Group Ltd